UCB S.A. (UCBJY) Stock Price & Analysis
UCB S.A. (UCBJY) — price $154.96 (-0.66%), as of the Nov 19, 2026 trading session; market cap $59.0B. Expected results Feb 25, 2027.
Educational signal · not a buy or sell recommendation · How to read this
UCB S.A. · UCBJY · Healthcare · Biotechnology
UCB S.A. is a biopharmaceutical enterprise dedicated to developing innovative treatments and solutions for individuals living with neurological and immunological diseases.
Price as of Nov 19, 2026
Key Statistics
No MoonshotScore yet: we have not published a score for this company.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $154.96 | |
| Change on the day | -0.66% | |
| 52-week range | $110.55–$168.76 | |
| Market capitalisation | $59.0B | — |
| Price / earnings (trailing) | 24.83 | |
| Shares traded on the day | 2.6K | |
| Beta (volatility vs the S&P 500) | 0.2 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
How to read these dates
Estimated dates can change.
Other perspectives
Council score for UCB (UCBJY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is UCB (UCBJY), and what does it report?
Short answer
UCB S.A. is a biopharmaceutical enterprise dedicated to developing innovative treatments and solutions for individuals living with neurological and immunological diseases. UCB S.A. (UCBJY) is classified as Healthcare / Biotechnology. Headquarters: Allée de la Recherche, 60, Brussels, BU, 1070, BE. It employs 10,117 people and is led by Jean-Christophe Tellier. In Q2 FY2026 it reported revenue of €4.35B and net income of €1.13B. The market values it at $59.0B.
What do the latest results show for UCB (UCBJY)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of €4.35B. Against analyst estimates the company has EPS beat 8 of the last 8 reports.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $4.91B Jul 30, 2026
- Latest report · revenue estimate
- $4.64B Jul 30, 2026
- Latest report · revenue vs estimate
- Above estimate Jul 30, 2026
- Latest report · EPS vs estimate
- Above estimate Jul 30, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Jul 30, 2026 | $4.91B | $4.64B | $3.9300 | $2.9100 |
| Feb 26, 2026 | $5.02B | $4.96B | $3.7900 | $2.9100 |
| Jul 31, 2025 | $3.99B | $3.74B | $2.0200 | $1.9300 |
| Feb 27, 2025 | $3.56B | $3.20B | $1.5500 | $1.3500 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | €4.35B | €1.13B | €2.92 (diluted) |
| Q4 FY2025 | €4.22B | €1.07B | €2.77 (diluted) |
| Q2 FY2025 | €3.49B | €475M | €1.22 (diluted) |
| Q4 FY2024 | €3.36B | €857M | €2.21 (diluted) |
What are the financial strengths and risks for UCB (UCBJY)?
Short answer · as of
The distress and quality screens read Altman Z 5.19 · Piotroski F 6. Trailing ratios: ROE 20.6% · ROA 8.3% · current ratio 1.20.
What should you watch next at UCB (UCBJY)?
Short answer · as of
The next earnings report is expected on Feb 25, 2027.
What the records here don't tell us
- Detailed statement figures are not shown because their conversion to USD has not been verified.
- No forward revenue or earnings estimate is on file.
- No insider Form 4 transaction falls inside the window this page reads.
- Fewer than two score snapshots exist, so no score trend is shown.
Checked against the records this page reads, on the dates shown above.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held UCBJY in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported UCBJY in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about UCB (UCBJY)?
UCB Healthcare Stock: Key Questions Answered
Research dated 2026-09-12; the full attribution is under Sources. The last question is answered from this page's own dated data, not from the research.
What does BIMZELX add to UCB’s immunology franchise?
BIMZELX extends UCB’s immunology reach across several inflammatory conditions already adjacent to Cimzia’s markets. Its contribution matters not only for sales growth but also for the product mix management expects to offset pricing pressure.
How do Nayzilam and UCB’s epilepsy medicines fit together?
Briviact, Vimpat and Keppra serve epilepsy management, while Nayzilam addresses seizure clusters through an emergency nasal spray. That gives UCB exposure to ongoing neurological treatment as well as acute intervention within the same franchise.
What is the UCBJY stock price today?
The last price recorded for UCB S.A. (UCBJY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 39 figures on this page — 33 from Financial Modeling Prep (FMP), 3 with no recorded source, 2 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com